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Kaposi’s sarcoma-associated herpesvirus (KSHV) is the first human virus known to encode dihydrofolate reductase
(DHFR), an enzyme required for nucleotide and methionine biosynthesis. We have studied the purified KSHV-DHFR enzyme
in vitro and analyzed its expression in cultured B-cell lines derived from primary effusion lymphoma (PEL), an AIDS-
associated malignancy. The amino acid sequence of KSHV-DHFR is most similar to human DHFR (hDHFR), but the viral
enzyme contains an additional 23 amino acids at the carboxyl-terminus. The viral DHFR, overexpressed and purified from E.
coli, was catalytically active in vitro. The Km of KSHV-DHFR for dihydrofolate (FH2) was 2.4 mM, which is significantly higher
than the Km of recombinant hDHFR (rhDHFR) for FH2 (390 nM). Km values for NADPH were similar for the two enzymes, about
1 mM. KSHV-DHFR was inhibited by folate antagonists such as methotrexate (K i: 200 pM), aminopterin (K i: 610 pM),
pyrimethamine (K i: 29 nM), trimethoprim (K i: 2.3 mM), and piritrexim (K i: 3.9 nM). In all cases, K i values for these folate
antagonists were higher for KSHV-DHFR than for rhDHFR. The viral enzyme was expressed at levels two- to tenfold higher
than hDHFR in PEL cell lines as an early lytic cycle gene. KSHV-DHFR mRNA and protein appeared from 6 to 24 h after
chemical induction of the KSHV lytic cycle. Epitope-tagged KSHV-DHFR and rhDHFR both localized to the nucleus of
transfected cells, while other KSHV nucleotide metabolism genes localized to the cytoplasm. DHFR activity was not essential
for viral replication in cultured PEL cells. Since hDHFR was not detectable in peripheral blood mononuclear cells (PBMCs),
KSHV-DHFR may function to provide increased DHFR activity in vivo in infected cells that have little or none of their own
enzyme. © 2000 Academic Press
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rINTRODUCTION
Kaposi’s sarcoma (KS) is the neoplasm most fre-
quently recognized among patients with AIDS (Goedert
et al., 1998). Using the technique of representational
difference analysis, Chang et al. (1994) discovered her-
esvirus-like sequences in KS lesions. These DNA se-
uences led to the identification of a novel herpesvirus,
ow known as Kaposi’s sarcoma-associated herpesvirus
KSHV) or human herpesvirus 8 (HHV8). KSHV is a gam-
aherpesvirus, related to Epstein–Barr virus (EBV) and
erpesvirus saimiri (HVS) (Weiss, 1996). The KSHV ge-
ome encodes several enzymes involved in nucleotide
ynthesis, including thymidine kinase (TK), thymidylate
ynthase (TS), ribonucleotide reductase (RR), and dihy-
rofolate reductase (DHFR) (Russo et al., 1996). Virally
ncoded DHFRs have been identified only in T4 bacte-
iophage and the g-two rhadinoviruses, including Rhe-
us rhadinovirus (RRV) (Searles et al., 1999), HVS, and
SHV.
DHFR, an enzyme that is ubiquitous in nature, serves
1 To whom correspondence and reprint requests should be ad-
ressed at Yale University School of Medicine, Department of Pediat-
ics, Division of Infectious Diseases, 333 Cedar Street 420 LSOG, New
aven, CT 06520-8064. Fax: (203) 785-6961. E-mail: george.miller@
ale.edu.
201o maintain pools of reduced folate cofactors needed for
ne-carbon donations in de novo purine synthesis, thy-
idylate synthesis, and synthesis of the amino acid
ethionine. DHFR is responsible for reduction of dihy-
rofolate (FH2), formed in the TS reaction, to tetrahydro-
olate (FH4), allowing continued function of the cyclic
athway which produces thymidylate for DNA synthesis.
n prokaryotes, which cannot take up exogenous folates,
HFR is also an essential element of the pathway for de
ovo folate biosynthesis. Intensive study of DHFR has
ed to the development of inhibitors which are widely
sed pharmacological agents in the treatment of cancer,
s immunosuppressive agents and as antibiotics against
acterial and protozoal infections.
The genomes of all human herpesviruses encode
ome enzymes involved in nucleotide metabolism. RR is
ncoded by all human herpesviruses. TK is encoded by
he alpha and gammaherpesviruses. TS and DHFR are
ncoded by some members of the human herpesvirus
roup; for example, varicella zoster virus (VZV) and KSHV
re the only members known to encode TS. The func-
ions of these viral enzymes in the viral life cycles and
athogenesis are not yet clear. None of the viral en-
ymes has been shown to be required for herpesvirus
eplication in tissue culture (Pyles et al., 1992). For ex-ample, the enzymes TK, RR, and deoxyuridine triphos-
phate hydroxylase (dUTPase) are not essential for repli-
0042-6822/00 $35.00
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202 CINQUINA ET AL.cation of herpes simplex virus 1 (HSV-1) in culture (Kit
and Dubbs, 1963; Fisher and Preston, 1986; Goldstein
and Weller, 1988; Daikoku et al., 1991); similarly, elimina-
ion of DHFR from the genome of HVS does not appear to
ffect viral replication or the immortalization of T-cells in
ulture (Desrosiers et al., 1985, 1986). Nevertheless,
these enzymes presumably play some crucial role in viral
pathogenesis in vivo. For example, HSV-1 TK seems to
e important for reactivation from latency (Field and
ildy, 1978; Coen et al., 1989; Tenser et al., 1989; Jacob-
son et al., 1993).
The viral nucleotide metabolism enzymes have proved
to be susceptible targets for antiviral therapy (Elion,
1993). HSV1-TK has been shown to catalyze phosphory-
lation of nucleoside analogs such as acyclovir (ACV) and
ganciclovir (GCV). This results in selective phosphoryla-
tion of ACV in virus-infected cells, with consequent mis-
incorporation of the fraudulent, replication-terminating
nucleotide into the viral DNA. Recently, three groups
have reported that KSHV is sensitive to antiviral drugs
such as cidofovir and GCV that work by this mechanism
(Kedes and Ganem, 1997; Medveczky et al., 1997; Can-
non et al., 1999). HSV1-RR inhibitors have also been used
n conjunction with ACV to decrease the competing
GTP pools and thus increase the probability of ACV
hosphorylation and misincorporation (Spector et al.,
1992). The viral enzymes have also found applications in
gene therapy. HSV1-TK has also been used as a trans-
fected “suicide” agent to facilitate tumor-cell killing by
ganciclovir (Klatzmann et al., 1998). Thus drugs that tar-
get the viral nucleotide metabolism genes may be useful
in treatment or prevention of KS.
In this report, we describe an initial study of KSHV-
DHFR, the first example of this enzyme encoded by a
human virus. An ultimate goal is to understand the role
KSHV-DHFR plays in viral replication and pathogenesis
and its possible value as a target for antiviral or antitu-
mor chemotherapy. We have compared the amino acid
sequence of KSHV-DHFR to those of other species. We
T
Comparison of Amino Acid Identity and Similar
DHFR KSHVa T4 bacteriophage
Human 50/66 24/37
VS 48/58 24/36
. cerevisiae 30/43 29/43
. coli 28/48 30/39
. falciparum 28/35 25/34
4 bacteriophage 14/28
Note. The P. falciparum-DHFR sequence represented is the DHFR d
a Numbers are % identity/% similarity.
b HVS 5 Herpesvirus saimiri.have expressed KSHV-DHFR in bacteria and purified the
protein. This allowed study of KSHV-DHFR kinetics andits inhibition by various folate antagonists, including
methotrexate (MTX), trimethoprim (TMP), pyrimethamine
(PYR), aminopterin (AMT), and piritrexim (PTX). We have
extensively studied KSHV-DHFR and human DHFR
(hDHFR) mRNA and protein expression in tissue culture.
Using epitope-tagging methods, we have found that
KSHV-DHFR and recombinant hDHFR (rhDHFR) localized
primarily to the nucleus, a finding that might provide
some insight into the debate over the intracellular local-
ization of the process of nucleotide metabolism (Prem
veer Reddy and Pardee, 1980; Leeds et al., 1985). We
have noted that levels of cellular DHFR are intrinsically
low in peripheral blood mononuclear cells (PBMCs),
which are thought to be susceptible to KSHV infection in
vivo (Ambroziak et al., 1995; Blasig et al., 1997). Viral
DHFR may therefore function to assist KSHV growth in
resting cells that have not been activated into the cell
cycle.
RESULTS
Amino acid sequence analysis
KSHV-DHFR is a 210-amino-acid (a.a.) protein with a
predicted mass of 24 kDa. Amino acid sequence com-
parisons showed that the KSHV-DHFR sequence is most
similar to the a.a. sequence of hDHFR, with which it
shares 50% identity and 66% similarity (Table 1). This
similarity is considerably less than the identity between
HVS-DHFR and hDHFR (83%). At the nucleotide level, the
percentage identity between KSHV-DHFR and hDHFR is
52%. Again, this is less than the nucleotide identity be-
tween HVS-DHFR and hDHFR (76%). Only the first 187 of
the 210 amino acids of KSHV-DHFR can be aligned with
hDHFR or other DHFRs (Fig. 1). The 23-a.a. “tail” is
unrelated to any known a.a. sequence and its function, if
any, is unknown. Bacteriophage T4 is the only virus that
is not a gammaherpesvirus known to encode a DHFR.
Only 165 out of 193 amino acids of bacteriophage T4
DHFR can be aligned with other DHFRs (Bernstein and
SHV-DHFR to DHFRs of Six Other Organisms
falciparum E. coli S. cerevisiae HVSb
34/46 35/55 35/45 83/87
31/43 33/51 33/45
38/49 28/40
25/40
of the bifunctional DHFR-thymidylate synthase enzyme.ABLE 1
ity of K
P.
omainBernstein, 1989). The sequence identity/similarity be-
tween KSHV-DHFR and T4 DHFR is only 14%/28%. Table
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203DIHYDROFOLATE REDUCTASE FROM KSHV1 shows the identity/similarity between KSHV-DHFR and
the DHFRs from the organisms whose DHFR a.a. se-
quences are shown in Fig. 1. KSHV-DHFR is most similar
to DHFR from eukaryotic cells and viruses but also
shares significant similarity with prokaryotic cellular and
viral DHFRs, particularly in the active site (Table 1 and
Fig. 1).
A more specific comparison of amino acids known to
be involved functionally in binding of dihydrofolic acid
(FH2) and NADPH by both prokaryotic and eukaryotic
HFRs revealed that KSHV-DHFR had identical or similar
mino acids at nearly all of these binding sites (Fig. 1).
FIG. 1. Amino acid sequence analysis of DHFR. This figure compares
boxes show an identity between sequences; shaded boxes show a sim
amino acid involved in NADPH binding or oxidation. HVS 5 Herpesviru
of the bifunctional DHFR-thymidylate synthase enzyme.owever, KSHV-DHFR has an aspartic acid (D) at a.a. 31,
here the corresponding a.a. in hDHFR is a glutamic Ncid (E). This difference may be interesting because this
s the amino acid believed to be responsible for proton
ransfer to FH2 (Brown and Kraut, 1992). Studies of the
E31D mutant of rhDHFR showed an increase in Km for
FH2 and NADPH (Blakley, 1995).
xpression and activity of KSHV-DHFR
The gene for KSHV-DHFR was cloned and expressed
n E. coli and the protein purified by affinity chromatog-
raphy (Fig. 2A). KSHV-DHFR purified from the extracts
was found to be catalytically active in vitro in a classical
HV-DHFR amino acid sequence to those of several other DHFRs. Black
F 5 amino acid involved in dihydrofolic acid binding or reduction. N 5
ri. The P. falciparum-DHFR sequence represented is the DHFR domainthe KS
ilarity.assay that measures the conversion of FH2 to FH4 and
ADPH to NADP1 (Fig. 2B). Analysis of the steady-state
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204 CINQUINA ET AL.kinetics of KSHV-DHFR revealed that the Km for FH2 was
2.4 mM, significantly higher than the value of 390 nM we
determined for rhDHFR (Table 2). A more accurate de-
termination of the Km was hindered by substrate inhibi-
tion that was observed at 8 mM FH2 for the viral enzyme
and 1 mM for rhDHFR (data not shown). Km values for
NADPH were about 1 mM for both the viral and human
enzyme (Table 2). The Km determination for NADPH was
monophasic, in contrast to the biphasic Km of NADPH
reported previously for rhDHFR (Appleman et al., 1990).
nterestingly, the rhDHFR E30D mutant was also reported
o have a monophasic Km for NADPH (Blakley, 1995). The
urnover number, or kcat, for KSHV-DHFR was about half
he value determined for rhDHFR (Table 2). Division of
cat by Km gives a measure of the overall catalytic effi-
ciency of the enzymes, with higher numbers being indic-
ative of a more efficient enzyme. From the kcat/Km num-
FIG. 2. Purification and activity of KSHV-DHFR. (A) Coomassie blue-st
of KSHV-DHFR, which was expressed as a fusion protein with an intein s
domain at the C-terminus of the intein element. Lane 1 shows 60
autocleavage. Lanes 2 and 3 show the two purest fractions after one r
of purification typically yielded 4 mg of pure protein per liter of E. coli. (B
n absorbance at 340 nM resulting from the reduction of dihydrofolic
icrograms of protein from the final pool of purified protein (Lane 3 o
TABLE 2
Steady-State Kinetic Values of KSHV-DHFR,
ntKSHV-DHFR, and rhDHFR
KSHV-
DHFR
ntKSHV-
DHFRa rhDHFRb
rhDHFR
(published)c
K m FH2 (mM) 2.4 6 0.5 2.2 6 0.5 0.4 6 0.1 0.12
K m NADPH (mM) 0.95 6 0.12 1.3 6 0.2 1.1 6 0.1 0.16–4.2
cat (s
21) 7.0 6 0.7 4.8 6 0.1 16.8 6 0.4 11 6 2
k cat/K m (s
21 mM21) 2.9 6 0.6 2.2 6 0.5 42 6 11 91.7
a ntKSHV-DHFR 5 KSHV-DHFR, 23-a.a. C-terminal truncation mutant.
s
k
b rhDHFR 5 recombinant human DHFR.
c From Appleman et al., 1990.bers in Table 2 it can be concluded that rhDHFR is at
least 14-fold more efficient than KSHV-DHFR under our
assay conditions.
To further evaluate the kinetic similarity between
KSHV-DHFR and eukaryotic DHFRs, experiments were
performed to determine whether KSHV-DHFR exhibited a
property attributed only to prokaryotic DHFRs known as
slow enzyme hysteresis (for a review, see Appleman et
al., 1989). Slow enzyme hysteresis arises as a result of a
slow transition between the nonbinding and binding con-
formations of an enzyme. DHFRs that exhibit slow en-
zyme hysteresis (i.e., prokaryotic DHFRs) are termed
classical DHFRs. Vertebrate DHFRs also exhibit a
change in conformation related to substrate binding, but
on a time-scale 1000-fold faster than invertebrate DHFRs.
These enzymes are termed nonclassical (Appleman et
al., 1989). Slow enzyme hysteresis was tested for by
looking for a difference in reaction velocity between
reactions that contained enzyme that was or was not
preincubated with substrate (Appleman et al., 1989). We
ound that KSHV-DHFR does not exhibit slow enzyme
ysteresis and thus, like vertebrate DHFRs, may be
ermed a nonclassical DHFR (data not shown).
Another property unique to vertebrate DHFRs is the
xistence of dual pH optima; prokaryotic DHFRs have
ne optimum (Blakley, 1969). The pH profile for KSHV-
HFR was determined by testing identical reactions
cross a broad range of pHs (4.5–9). The viral DHFR
xhibited dual pH optima at pH 4.5 and 8 (data not
DS–PAGE containing the ultimate and penultimate steps in purification
ving element at the C-terminal end of KSHV-DHFR and a chitin-binding
rotein obtained after a chitin bead affinity column purification and
r a G-75 Sephadex gel filtration column (25 mg per lane). This method
resentative KSHV-DHFR activity assay reaction depicting the decrease
o tetrahydrofolic acid and the oxidation of NADPH to NADP1. Three
el illustrated in A) was used in this particular reaction.ained S
elf-clea
mg of p
un ove
) A rephown). This is further evidence that the viral DHFR is
inetically similar to vertebrate DHFRs.
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205DIHYDROFOLATE REDUCTASE FROM KSHVA truncation mutant of KSHV-DHFR, lacking the C-
terminal 23-a.a. region, was also constructed (ntKSHV-
DHFR). The steady state properties of ntKSHV-DHFR are
shown in Table 2. The Km and kcat values for the trunca-
tion mutant were not significantly different from those of
the wild-type enzyme.
Inhibition analysis of KSHV-DHFR
K i values for five known inhibitors of DHFR were ob-
ained using both KSHV-DHFR and rhDHFR (Table 3). The
i values determined for KSHV-DHFR were higher than
hose for rhDHFR in all cases. The K i determination of
AMT for KSHV-DHFR is shown in Fig. 3. The curvature of
the plotted line indicates that AMT is not a “stoichiomet-
ric” inhibitor of KSHV-DHFR as it is known to be for
hDHFR (Ercikan et al., 1993). In the case of a stoichio-
metric inhibitor, such as MTX, PTX, or AMT for hDHFR,
the velocity versus [inhibitor] plot is a straight line until
the concentration of inhibitor equals the concentration of
enzyme, which results from the enzyme’s being titrated
out of action through extremely tight binding of the in-
hibitor (Werkheiser, 1960). Thus stoichiometric inhibitors
can be used to determine the amount of enzyme in
solution (Bertino et al., 1970). None of the inhibitors
ested proved to be a stoichiometric inhibitor of KSHV-
HFR. Taken together, these preliminary studies did not
dentify an inhibitor with selective activity against KSHV-
HFR.
omparison of expression of KSHV-DHFR and hDHFR
RNA in primary effusion lymphoma (PEL) cell lines
The kinetic class of KSHV lytic cycle genes has been
etermined in cultured PEL cell lines that have been
reated with chemicals that induce the viral lytic cycle
Sun et al., 1999). Nicholas et al. (1997) reported the
ppearance of a 1.2-kb transcript of the viral DHFR gene
TABLE 3
Comparison of the Sensitivity of KSHV-DHFR and Recombinant
Human DHFR to Five Known Inhibitors of DHFR
Drug KSHV-DHFRa rhDHFRb rhDHFR (published)
Methotrexate 200 6 18 pM 9 6 2 pM 3.4 6 1.2 pMc
Aminopterin 610 6 20 pM NDd 14.6 6 0.1c, 1.8 pMe
Piritrexim 3.9 6 0.4 nM 8 6 2 pM 7.7 6 1.2 pM f
Pyrimethamine 27 6 3 nM 1.0 6 0.2 nM 1.15 6 0.06 nM f
Trimethoprim 2.3 6 0.2 mM 0.81 6 0.02 mM 0.96 6 0.3 mMc
a Numbers are the K i values.
b rhDHFR 5 recombinant human DHFR.
c From Appleman et al., 1988b.
d ND 5 not determined.
e From Margosiak et al., 1993.
f From Ercikan-Abali et al., 1996.n the HBL6 cell line, which contains both the KSHV and
BV genomes, 12 h after induction of the lytic cycle. We
Dxamined the expression kinetics of the viral DHFR gene
n the BC-1 PEL cell line, which also contains both EBV
nd KSHV, and in the PEL cell line HH-B2, established in
ur laboratory, which is infected only with KSHV (Fig. 4A).
e detected a 1.1-kb transcript using a single-stranded,
ligonucleotide probe specific for KSHV-DHFR mRNA.
he 1.1-kb KSHV-DHFR mRNA appeared 13 h after treat-
ent with butyrate and was present until 48 h after
hemical induction (Fig. 4A and data not shown). When
he same blots were probed with an oligonucleotide
omplementary to hDHFR, the 3.8-kb hDHFR transcript
as present until 24 h following chemical induction, after
hich time it became undetectable (Chen et al., 1984).
he same experiments were also carried out using the
ell line HH514–16 (Cl-16), a Burkitt-lymphoma derivative,
hich is infected only with EBV, and the B-lymphoma cell
ine BJAB, which is not virally infected. KSHV-DHFR
RNA was not detected in either of these cell lines (data
ot shown). In both these cell lines, a decrease in the
mount of hDHFR transcript, quantitatively similar to that
een in the KSHV positive PEL cell lines, was seen 24 h
fter treatment with butyrate (data not shown).
The relative increase in KSHV-DHFR mRNA and the
elative decrease in hDHFR mRNA up to 48 h after
hemical induction of the lytic cycle, were quantified
sing a phosphorimager (Figs. 4B and 4C). Treatment
ith butyrate caused a more than 30-fold increase in the
ignal of KSHV-DHFR mRNA in the BC-1 cell line and a
ixfold increase in the KSHV-DHFR signal in the HH-B2
ell line (Fig. 4B). Conversely, treatment with butyrate
esulted in a 27-fold decrease in the signal of hDHFR
RNA in BC-1 cells and a 63-fold decrease in HH-B2
ells as compared to a sample that was not treated with
rugs.
FIG. 3. Determination of the K i of aminopterin for KSHV-DHFR. Vary-
ng concentrations of AMT (;1–300 nM) were added to the standardHFR activity assay to generate an inhibition curve. K i was determined
by extrapolation to this curve.
r
t
f
d
panel A were rearranged to preserve continuity in the presentation of
data from experiments with the two cell lines.
206 CINQUINA ET AL.Other chemical agents known to activate the KSHV
lytic cycle were also shown to induce expression of
KSHV-DHFR mRNA. For example, tetradecanoyl phorbol
acetic acid (TPA) induced viral DHFR mRNA expression
in the BCBL-1 cell line and trichostatin A (TSA), a histone
deacetylase inhibitor, activated KSHV-DHFR mRNA ex-
pression in the BC-1 cell line (data not shown).
Expression of KSHV-DHFR and hDHFR in PEL cell
lines
To demonstrate that KSHV-DHFR protein was ex-
pressed in infected cells, we developed polyclonal anti-
bodies to KSHV-DHFR by immunizing rabbits with the
viral enzyme that was produced in E. coli and purified
(Fig. 2A). The antibody to viral DHFR did not cross-react
with rhDHFR that was expressed and purified from E. coli
(data not shown). Moreover, the rabbit antiviral DHFR
antibody did not detect hDHFR that was present in cul-
tured B-cell lines (Fig. 5).
We determined the relative kinetics of expression of
viral and cellular DHFR protein in a series of cultured
B-lymphoma cell lines, including BC-1, HH-B2, BCBL-1,
FIG. 5. Comparison of KSHV-DHFR and hDHFR protein in two B-cell
lymphoma cell lines. Shown are Western blots probed with monospe-
cific polyclonal rabbit antibodies to KSHV-DHFR, hDHFR, and b-actin.
The blots illustrate the levels of KSHV-DHFR and hDHFR over a 48-h
time course following treatment of the BC-1 PEL cell line and Cl-16
Burkitt lymphoma cell line with butyrate. NI 5 noninduced.FIG. 4. Comparison of KSHV-DHFR and hDHFR mRNA after treat-
ment of two primary effusion lymphoma (PEL) cell lines with butyrate.
(A) Northern blot illustrating the expression of human and viral DHFR
transcripts over a 48-h time period after treatment of the BC-1 and
HH-B2 PEL cell lines with butyrate. The H1 component of RNase P was
used to control for loading. NI 5 noninduced. (B) Quantitation of the
elative amounts of KSHV-DHFR mRNA following treatment with bu-
yrate. (C) Quantitation of the relative amounts of human DHFR mRNA
ollowing treatment with butyrate. The relative amounts of mRNA were
etermined by phosphorimaging of the data in panel A. Some lanes inBC-3, Cl-16, and BJAB (Fig. 5, Table 4, and data not
shown). Immunoblots prepared from untreated cell ex-
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207DIHYDROFOLATE REDUCTASE FROM KSHVtracts or from extracts of chemically induced cells were
reacted with antibodies to KSHV-DHFR and hDHFR.
KSHV-DHFR was not detected in cells, such as Cl-16 and
BJAB, which lack the KSHV genome (Fig. 5 and data not
shown). In PEL cell lines containing KSHV, viral DHFR
was invariably induced 24 h after chemical treatment.
Immunoreactive, viral protein persisted for at least 48 h.
The amount of viral DHFR detected in chemically in-
duced cells varied among the PEL cell lines (Table 4).
Equal amounts of hDHFR were detected in KSHV-nega-
tive and KSHV-positive cell lines. The abundance of
hDHFR was only minimally affected by chemical treat-
ment (Fig. 5, Table 4).
In cultures treated with butyrate, hDHFR protein was
present in the cell extracts even after the hDHFR mRNA
was no longer detectable (compare Figs. 4A and 5).
hDHFR protein is known to have a long half-life of be-
tween 11 and 20 h (Jackson and Huennekens, 1973;
Domin et al., 1982). Therefore hDHFR produced in the
first 20 h after butyrate treatment is likely to be present at
48 h.
TABLE 4
Estimation of the Number of KSHV-DHFR and
hDHFR Molecules Per Cell
KSHV-DHFR
Cell line (virus)
Copies per cella
48-h NI 48-h but.
With correction,
assuming 25%
inductionb
48-h NI 48-h but.
BC-1 (KSHV/EBV) 5 3 103 1.6 3 105 5 3 103 6.4 3 105
HH-B2 (KSHV) 6 3 103 1 3 104 6 3 103 4 3 104
BCBL-1 (KSHV) 4 3 103 2 3 104 4 3 103 8 3 104
BC-3c (KSHV) 7 3 103 1.6 3 105 7 3 103 6.4 3 105
Human DHFR
Cell line (virus)
Copies per cella
48-h NI 48-h but.
BC-1 (KSHV/EBV) 5 3 104 6 3 104
HH-B2 (KSHV) 2 3 104 2 3 104
BCBL-1 (KSHV) 3 3 104 4 3 104
BC-3c (KSHV) 3 3 104 4 3 104
CL-16 (EBV) 1 3 104 4 3 104
BJAB (none) 1 3 104 4 3 104
Note. The data for all cell lines except the BC-3 cell line was obtained
48 h after subculture in the presence or absence of butyrate.
a NI 5 noninduced; but. 5 butyrate-treated.
b The corrected values assume that approximately 25% of the cells
were induced into the lytic cycle.
c The BC-3 cell line was induced with TPA and butyrate.Consistent with the mRNA results, KSHV-DHFR protein
expression was also increased following treatment witha number of other inducing agents including TPA and
TSA, which are known to activate the KSHV lytic cycle
(data not shown).
Quantitation of KSHV-DHFR and hDHFR
To estimate the amount of KSHV-DHFR per cell in
uninduced and lytically induced extracts, we performed
phosphorimage analysis of immunoblots, comparing the
signal from cell extracts with the signal from known
amounts of purified viral and human DHFR protein (Table
4). The amount of KSHV-DHFR in uninduced cultures,
from 4 to 7 3 103 molecules per cell, was remarkably
imilar among all the KSHV-infected PEL cell lines
ested. Forty-eight hours after chemical induction of the
ytic cycle, there was an increase in viral DHFR content
n all the PEL cell lines. The BC-1 and BC-3 cell lines
ontained the highest amounts of viral enzyme, almost
0-fold the amounts detected in the BCBL-1 or HH-B2
ell lines. If it is assumed that about 25% of cells were
hemically induced into the lytic cycle, viral DHFR con-
ent per cell rose from a minimum of sixfold (in HH-B2
ells) to a maximum of 128-fold (in BC-1 cells).
The copy number of hDHFR varied from 1 to 5 3 104
molecules per cell in the six cell lines tested (Table 4).
This number increased about fourfold following butyrate
treatment of the two KSHV-negative cell lines, but did not
measurably change in the KSHV-positive cells. Compar-
ing the level of viral and cellular DHFR in chemically
treated cultures, there was at least twofold as much viral
DHFR as cellular DHFR in the minimally responsive
HH-B2 and BCBL-1 cell lines and more than 10-fold as
much viral as cellular DHFR per cell in the maximally
responsive BC-1 and BC-3 cell lines.
To compare the amount of hDHFR estimated to be
present in the cultured B-lymphoma cells with the
FIG. 6. Amount of hDHFR in human peripheral blood mononuclear
cells (PBMC) depleted of CD-3 positive T-lymphocytes. This immuno-
blot, probed with antiserum to hDHFR, compares the level of hDHFR in
a sample of 4 3 106 CD3-depleted human PBMCs with known amounts
f recombinant hDHFR. The secondary probe was 125I-labeled protein
A. The blot was exposed for 14 days. Ninety picograms of hDHFR is
roughly equivalent to 650 copies/cell in a 4 3 106 cell sample. The blot
was probed with mouse monoclonal antibody to human b-actin to
control for loading of the cell sample.
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a sample of PBMCs that were depleted of CD3-positive
T-cells, leaving mainly B-cells and monocytes, the cell
types in which KSHV has been detected in the blood
(Ambroziak et al., 1995; Blasig et al., 1997). This experi-
ment (Fig. 6) showed that hDHFR was undetectable in
this cell population. The smallest amount of hDHFR that
could be detected was 90 pg, which corresponds to
approximately 650 copies per cell. Thus, B-cell primary
effusion lymphomas grown in tissue culture contain at
least 15- to 77-fold more hDHFR than peripheral blood
B-cells and monocytes.
Intracellular localization of KSHV-DHFR, rhDHFR, and
KSHV-TS, -TK, -RRa, and -RRb
The next series of experiments explored two ques-
tions: (1) whether viral and cellular DHFR were found in
the same or different cellular compartments and (2)
whether other enzymes involved in nucleotide metabo-
lism encoded by KSHV were present in the same cellular
compartment as DHFR. When expressed with an N-
FIG. 7. Intracellular localization of KSHV-DHFR, rhDHFR, and KSHV
SHV-DHFR, rhDHFR, or KSHV-TS with an N-terminal flag tag. Cells we
pitope, which was detected with a rabbit antimouse IgG TRITC conjug
B–D) Cells transfected with KSHV-DHFR/flag tag. (E) Cells transfectedterminal flag tag, both KSHV-DHFR and rhDHFR were
localized almost exclusively to the nuclei of the Chinesehamster ovary (CHO) cells and excluded nucleoli (Figs.
7B–7D and 7E, respectively). Although there were a few
cells also containing varying amounts of speckled fluo-
rescence in the cytoplasm, there were no fluorescent
cells that lacked nuclear staining for either human or
viral DHFR. These results were confirmed in COS cells
and in the HH-B2 PEL cell line (data not shown). KSHV-
DHFR and rhDHFR protein expressed as a C-terminal
green-fluorescent fusion protein were also localized to
the nucleoplasm (data not shown). The 23-a.a. C-terminal
KSHV-DHFR truncation mutant was also localized exclu-
sively to the nucleus.
By contrast, KSHV-TS appeared to be localized com-
pletely to the cytoplasm (Figs. 7F and 7G), as did
KSHV-TK and KSHV-RRa (data not shown). KSHV-RRb
was the only gene tested that was seen to localize to the
cytoplasm in some cells and to the nucleus of other cells
(data not shown). The localizations of KSHV-TS, -TK,
-RRa, and -RRb were similar in CHO cells, COS cells, and
in the HH-B2 PEL cell line. The localization of these four
enzymes was similar, whether constructs contained an
O cells were transfected with vector alone or with vector containing
and incubated with a mouse monoclonal antibody to the M2 flag-tag
condary antibody. (A) Cells shown were transfected with vector alone.
hDHFR/flag tag. (F, G) Cells transfected with KSHV-TS/flag tag.-TS. CH
re fixedN-terminal myc-epitope tag or an N-terminal flag tag
(data not shown).
—Conti
209DIHYDROFOLATE REDUCTASE FROM KSHVCotransfection of flag-tagged KSHV-DHFR, a nuclear
product, and myc-tagged KSHV-TS, a cytoplasmic prod-
uct, into CHO cells allowed for double-staining, which
showed no evidence of association of the two enzymes
(data not shown).
Effects of AMT on KSHV replication in culture
To determine whether DHFR activity is necessary for
KSHV replication, BC-3 cells were first adapted to growth
in media containing hypoxanthine (H), aminopterin (A),
and thymidine (T) (HAT). AMT inhibited DHFR activity in
HAT-adapted BC-3 cells. When such cells were deprived
of H and T, and exposed to AMT, they failed to proliferate
FIG. 7(Fig. 8A). HAT-adapted BC-3 cells, subcultured in me-
dium with no supplement, with HT only, with HAT, or withAMT, were treated with TPA and butyrate to induce the
KSHV lytic cycle. As an index of viral replication, the
amount of viral DNA was measured by Southern blotting
followed by phosphorimaging (Fig. 8B). As an indirect
measure of viral replication the amount of sVCA, a late
protein, was detected by immunoblotting (Fig. 8C). Treat-
ment of HAT-adapted BC-3 cells with TPA and butyrate
caused an increase in viral DNA content. A similar in-
crease in viral DNA content was observed whether or not
the cells were provided with H and T and whether or not
they were treated with 400 nM AMT (Fig. 8B). Similarly,
under all conditions there was an increase in the content
of sVCA, a late gene whose expression is dependent on
nuedviral DNA replication (Lin et al., 1997; Chan et al., 1998).
Although there were slight decreases in viral DNA con-
gs
aFIG. 8. Viral DNA content and expression of KSHV small capsid antigen (sVCA) in the presence of aminopterin (AMT). BC-3 cells were adapted to
row in HAT media (100 mM hypoxanthine [H], 16 mM thymidine [ T ], and 400 nM AMT). Adapted cells were washed extensively and subcultured. They
were induced to enter the lytic cycle by treatment with TPA and butyrate in the presence of HT alone, HAT, AMT alone, or no supplement. Cell extracts
were harvested at 48 and 72 h. (A) Growth curves for HAT-adapted BC-3 cells over a 120-h time course. (B) Total genomic DNA was extracted, digested
with EcoRI, and separated on an agarose gel. The Southern blot was probed with a 32P-labeled fragment of DNA containing ORF65 (sVCA) to measure
viral DNA content. Loading was controlled for by probing the Southern blot with a 32P-labeled human b-actin DNA fragment. (C) Cell extracts were
eparated by SDS–PAGE. The immunoblot was probed with rabbit antibody to sVCA, followed by 125I-labeled protein A and mouse monoclonal
ntibody to human b-actin to control for loading. NI 5 noninduced. T/B 5 treated with TPA and butyrate. Some samples shown in (B) were rearranged
to preserve continuity.
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211DIHYDROFOLATE REDUCTASE FROM KSHVtent and in sVCA expression in the presence of AMT
(Figs. 8B and 8C), these experiments indicated that con-
centrations of AMT that are known to inhibit both viral
and cellular DHFR enzyme activity (Table 3), and were
shown to inhibit proliferation of BC-3 cells (Fig. 8A), were
unable to inhibit KSHV replication in cultured PEL cells.
Thus we conclude that DHFR activity is not obligatory for
viral replication in vitro.
DISCUSSION
In this report, we describe the properties of the DHFR
enzyme encoded by KSHV, the most recently identified
human herpesvirus. DHFR is known to be encoded by
only two classes of DNA viruses, namely bacteriophage
T4 and the rhadinovirus subgroup of the gammaherpes-
viruses, whose members include KSHV, Herpesvirus
saimiri, and RRV (Searles et al., 1999).
Based on nucleotide and amino acid homologies, the
KSHV gene seems to have arisen from the primate cel-
lular genome. However, the viral gene product has a
23-a.a. C-terminal appendage that so far does not ap-
pear to affect either enzymatic activity or nuclear local-
ization. Unexpectedly, KSHV-DHFR as well as its human
cellular counterpart were found to localize in the nu-
cleus. Following chemical induction of the KSHV lytic
cycle, viral enzyme was expressed to high levels, more
than 105 copies per cell. However, based on studies with
he folate inhibitor aminopterin, to which KSHV-DHFR is
usceptible, the viral enzyme did not appear to be re-
uired for lytic viral DNA replication or viral late gene
xpression in cultured PEL cell lines.
rigin of the gammaherpesvirus DHFR gene
The nucleotide sequence of the KSHV-DHFR gene is
0% identical to that of the human DHFR gene; the
VS-DHFR gene is 76% identical to the human DHFR
ene, and the RRV-DHFR gene is 63% identical to the
uman DHFR gene. The amino acid sequence of KSHV-
HFR is 50% identical, HVS-DHFR is 83% identical, and
RV-DHFR is 58% identical to human DHFR. These com-
arisons strongly suggest that the DHFRs of the three
rimate gammaherpesviruses and human DHFR share a
ommon ancestor. It is likely that the viral genes arose
rom their cellular counterparts by reverse-transcription
r recombination. However, the gene for KSHV-DHFR is
ocated in the portion of the KSHV genome that also
ncodes cytokines and chemokines (Russo et al., 1996),
hile the genes for HVS-DHFR (Albrecht et al., 1992) and
RV-DHFR (Searles et al., 1999) are located in a nonan-
logous position of their respective genomes. This sug-
ests that KSHV may have acquired its DHFR in an event
hat was distinct from that which occurred in HVS or RRV.
Moreover, KSHV-DHFR has a 23-a.a. C-terminal “tail”
ot found in HVS-, RRV-, or human DHFR. The amino acidequence of the KSHV-DHFR 23-a.a. tail is not similar to
ny amino acid sequence in the protein data bases.
owever, there is a region downstream of the stop codon
f the human DHFR gene which is 42% identical in
ucleotide sequence to the region of KSHV-DNA encod-
ng the 23-a.a. C-terminal tail of viral DHFR. This finding
rovides further support for the idea that KSHV-DHFR
rose from cellular DHFR by retrotransposition and that
his event was separate from the one(s) which led to the
cquisition of DHFR by HVS and RRV.
HFR localizes to the nucleus
We found, surprisingly, that epitope-tagged versions of
oth viral and cellular DHFR enzymes were located ex-
lusively in the nucleus of transfected cells (Figs. 7B–7E).
uclear localization of viral DHFR was independent of
he epitope tag, the cell line, its state of confluence at the
ime of transfection, or the transfection method em-
loyed. These findings were unexpected because earlier
mmunofluorescence experiments made no suggestion
hat DHFR enzyme might be nuclear (Grill et al., 1984).
Early cell fractionation experiments showed that DHFR
activity from rat liver was primarily located in the cyto-
plasm and mitochondria (Brown et al., 1965). Studies
using fluorescence-labeled MTX (F-MTX) showed that
F-MTX, which was competent to bind DHFR, was exclu-
sively in the cytoplasm (Kaufman et al., 1978). Further-
more, other mammalian cellular enzymes such as TK and
RR that are involved in nucleotide metabolism are lo-
cated in the cytoplasm (Leeds et al., 1985; Kucera and
aulus, 1986; Johansson et al., 1997). However, although
S was once thought to be exclusively cytoplasmic
Kucera and Paulus, 1986), early and more recent evi-
ence indicates that TS is also found in the nucleoplasm
Brown et al., 1965; Samsonoff et al., 1997).
The discovery of DHFR nuclear localization might lend
ome credence to the concept of a multienzyme “repli-
ase” complex involved in dNTP synthesis (Prem veer
eddy and Pardee, 1980). This hypothetical complex
omprised of DHFR, TK, TS, RR, nucleotide diphosphate
inase, and DNA polymerase is thought to form in the
ucleus during S phase. It is postulated that the enzymes
isassociate and leave the nuclear compartment after S
hase (Prem veer Reddy and Pardee, 1980).
Our experiments, however, showed that human and
iral DHFR were always present in the nucleus, even
hen the cells were confluent (i.e., in Go). Furthermore,
imilar experiments showed that KSHV-TS, -TK, and -RRa
were exclusively in the cytoplasm. Moreover, in infected
PEL cells viral DHFR was observed to be distributed
diffusely through the nucleus and not in discrete gran-
ules, which might be expected to comprise a viral “repli-
tase” complex or a compartmentalized site of viral DNA
replication (de Bruyn Kops et al., 1998).
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Cancer chemotherapy drugs such as aminopterin and
methotrexate target cellular DHFR and, to a lesser ex-
tent, other folate-binding enzymes. The primary basis of
this therapy is thought to be the high nucleotide require-
ment of rapidly dividing cancer cells. However, these
drugs are not selective, for they also inhibit proliferation
of rapidly dividing normal cells. The DHFR enzymes of
some bacteria are also targets of antibiotics, such as
trimethoprim. The basis of selective action of tri-
methoprim is that the inhibitor binds more tightly to the
bacterial than to the mammalian DHFR enzyme. There-
fore, we made preliminary efforts to identify a compound
that would bind more avidly to KSHV-DHFR than to cel-
lular DHFR (Table 3). KSHV-DHFR was less sensitive
than rhDHFR to all of the five inhibitors studied. A pos-
sible reason for the high K i of MTX for KSHV-DHFR is that
n the viral enzyme, a methionine replaced phenylalanine
t position 32. In human DHFR this amino acid plays a
ey role in binding MTX (Schweitzer et al., 1989; Tsay et
l., 1990).
Although we have so far been unable to identify a
ompound that selectively inhibits viral DHFR, the use of
KSHV-DHFR inhibitor might find clinical applicability in
ombination with another class of antiviral drug. KSHV
eplication is sensitive to viral DNA polymerase inhibi-
ors such as phosphoformate and chain terminators
uch as ganciclovir and penciclovir (Kedes and Ganem,
997; Medveczky et al., 1997). Therefore, these drugs
might be used in combination with a DHFR inhibitor such
as methotrexate in the treatment of Kaposi’s sarcoma or
other KSHV-associated diseases such as primary effu-
sion lymphoma or multicentric Castleman’s disease.
KSHV-DHFR is not essential for viral replication in
cultured PEL cell lines
Our experiments with aminopterin showed that amounts
of the inhibitor that block enzymatic activity in vitro and that
inhibit cellular proliferation do not block KSHV lytic viral
DNA replication or late gene expression (Fig. 8). Therefore,
KSHV-DHFR is not necessary for viral replication in tissue
culture. These results agree with experiments done in
KSHV’s counterpart HVS, in which HVS-DHFR was geneti-
cally eliminated without affecting HVS replication or immor-
talization (Desrosiers et al., 1985, 1986).
What explains this result? The absence of BC-3 cellu-
lar proliferation in the presence of AMT excludes the
possibility that HAT-adapted BC-3 cells have developed a
cellular or viral DHFR enzyme that is resistant to the
action of AMT. Since BC-3 cellular proliferation is inhib-
ited when AMT is present and hypoxanthine and thymi-
dine are absent, these nucleotide precursors may be
limiting for cellular DNA replication but not for viral DNA
replication. The nucleotide precursors for viral replica-
tion may come from intracellular pools, from the serum in
b
bthe culture medium, or breakdown of cellular DNA during
the lytic cycle of KSHV. Early experiments suggested that
herpes simplex virus 2 derived some of its nucleotides
from degradation of cellular DNA (Nutter et al., 1985).
However, host cell DNA is not incorporated into the
genome of herpes simplex virus 1 (Prichard and Ship-
man, 1995).
Why does KSHV encode DHFR?
We have considered four possible answers to this
question: (1) the viral DHFR enzyme is a structural com-
ponent of the virion; (2) viral DHFR forms an essential
component of a viral “replitase” complex consisting of
virally encoded enzymes required for nucleotide metab-
olism; (3) the viral DHFR enzyme is required because the
virus shuts off host cell macromolecular synthesis; and
(4) a viral DHFR enzyme is needed because levels of the
enzyme in the target cells susceptible to the virus in vivo
are too low to meet the requirements of viral replication.
The first two hypotheses were provoked by studies of
DHFR in bacteriophage T4. Early experiments suggested
that the DHFR of T4 bacteriophage was incorporated into
the basal tail plate of the phage (Wang and Mathews,
1989), but later immunoblot assays determined that this
result was due to an artifact of the antibody preparation
(Chen et al., 1995). Using an immunoblot assay with
antibodies to KSHV-DHFR, we were unable to detect any
immunoreactive viral DHFR enzyme protein in virions
produced from TPA-treated BC-3 cells (data not shown).
T4-DHFR was shown to be a component of a multien-
zyme dNTP-synthesizing complex, as postulated by the
replitase model (Wheeler et al., 1996). However, our lo-
calization studies (Fig. 7) suggest that viral DHFR and TS
are located in different subcellular compartments, a find-
ing which is not consistent with the replitase model.
We have noted that KSHV lytic replication in BC-1 and
HH-B2 PEL cells induced by sodium butyrate is accom-
panied by a dramatic decline in the abundance of cellu-
lar mRNAs (Miller et al., 1997), including host-cell DHFR
mRNA (Fig. 4C). This effect is selective; viral mRNAs,
including that of KSHV-DHFR increase in abundance
following butyrate treatment (Figs. 4A and 4B). While this
effect could result from a viral mechanism that shuts off
host-cell mRNA synthesis or degrades host-cell mRNAs,
a more likely explanation is that the effect is directly
caused by treatment with butyrate, independent of viral
replication. A decrease in host-cell DHFR mRNA of sim-
ilar magnitude was seen following butyrate treatment of
B-cell lines lacking KSHV (not shown).
How might butyrate lead directly to inhibition of cellu-
lar DHFR mRNA expression? Expression of the hDHFR
gene is regulated during the cell cycle. There is an
increase in cellular DHFR transcription at the G1/S-phaseorder (Slansky et al., 1993). This increase is regulated
y the transcription factor E2F. Histone deacetylase
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213DIHYDROFOLATE REDUCTASE FROM KSHV(HDAC) inhibitors, such as butyrate and TSA, can acti-
vate the transcription of many genes, but they also arrest
cells in the G1 phase of the cell cycle (Gilbert and Weigle,
993). When E2F is bound to retinoblastoma protein (Rb)
uring G1, it acts as a repressor of cell-cycle genes such
as DHFR (Hamel et al., 1992; Weintraub et al., 1995). In
some cases, treatment with HDAC inhibitors such as
butyrate and TSA does not relieve the E2F-Rb repression
(Luo et al., 1998). Thus, in KSHV-positive PEL cell lines,
butyrate may exert opposing effects on the cellular and
viral DHFR genes. The viral gene may be activated,
perhaps as a result of hyperacetylation of the chroma-
tinized viral genome, while the cellular gene may be
repressed as the result of G1 arrest and E2F repression
caused by treatment with butyrate.
Cellular DHFR is a stable protein that persists after cel-
lular DHFR mRNA is undetectable (Fig. 5) (Jackson and
Huennekens, 1973; Domin et al., 1982). This finding sug-
ests that the level of cellular DHFR in cultured PEL cells is
dequate to meet the dNTP requirements for KSHV DNA
eplication, even after the shut-off of host-cell mRNAs. How-
ver, a fuller exploration of this possibility should address
he abundance of cellular versus viral DHFR enzyme in
ndividual cells undergoing lytic viral replication. Since less
han 25% of cultured PEL cells undergo lytic viral replication
ollowing application of a chemical-inducing stimulus, a
ecrease in the content of cellular DHFR in these cells
ight not be evident when viewed against the background
f the cellular population as a whole.
In our view, the most likely explanation for the require-
ent for a virally encoded DHFR enzyme is that the virus
ay replicate in quiescent cells, such as lymphocytes or
onocytes, that contain low levels of cellular DHFR and
y inference low levels of FH4 and dNTPs (Fig. 6). The
level of cellular DHFR is at least 20-fold higher in cul-
tured PEL cells than in primary PBMCs (Table 4). There-
fore, cultured PEL cells are likely to contain pools of
dNTPs that are considerably higher than those found in
resting mononuclear cells. These pools may explain why
inhibition of the cellular enzyme with AMT is not signif-
icantly detrimental to viral replication in PEL cells (Fig. 8).
If KSHV were to use the cellular DHFR enzyme for its lytic
replication in resting cells, it might be required to stim-
ulate the cell into the late G1 phase of the cell cycle when
cellular DHFR is made (Slansky et al., 1993). Thus far
KSHV, unlike the related gammaherpesvirus EBV, which
does not encode DHFR, has not been shown to be
capable of activating infected lymphoid cells into DNA
synthesis.
MATERIALS AND METHODS
Sequence analysis
All sequence comparison and analysis was done us-
ing BLASTP, BESTFIT, and GAP from the GCG software
package.Expression and purification of KSHV-DHFR
The KSHV-DHFR gene was cloned from genomic DNA
from the BC-1 cell line using PCR. The 59 primer used
was 59CTCGCGCCATGGATCCTACACTTTACTGTGTA39.
The 39 primer used was 59TGCCGGCTCTTCCGCAC-
GAAGTCTCACTGAAGGGCG39. The PCR product was li-
gated into the pCYB3 vector (New England Biolabs). This
vector contains a 39-autocleaving intein tag and a chitin-
binding domain 39 to the intein tag. The plasmid was
transformed into BL21(DE3) E. coli (Novagen) for expres-
sion. The culture was induced overnight at room temper-
ature in 0.4 mM IPTG. The bacteria were pelleted and
resuspended in 30 mL buffer A (20 mM Tris–HCl, pH 8.0;
500 mM NaCl; 1 mM EDTA; and 0.1% Triton X-100) per
liter of culture. The resuspended bacteria were lysed
using a French press. The resulting lysate was centri-
fuged at 15,000g for 1 h. The supernatant (soluble frac-
tion) was then applied to a 5-mL chitin bead column
(New England Biolabs, Beverly, MA). The column was
washed with 1 L of buffer A. After the wash, the column
was flushed with buffer A containing 50 mM DTT and left
overnight. Fractions were collected and protein concen-
tration was determined by Coomassie protein assay
(Pierce, Rockford, IL). DHFR activity assays were per-
formed to determine the specific activity of the pure
protein. To further purify the protein, the sample was first
concentrated and then applied over a G-75 Sephadex gel
filtration column connected to a Pharmacia LKB FPLC
system. Peak fractions were collected and assayed for
activity. The buffer used for FPLC was buffer A with 150
mM NaCl. The protein eluted at a retention volume of 30
mL, corresponding approximately to the molecular
weight of 46 kDa, which implies that the enzyme is a
dimer in solution. These fractions were examined elec-
trophoretically on 12% polyacrylamide gels to determine
purity (Fig. 2A). There were no detectable contaminants
in the purest fractions.
The mutant that eliminated the C-terminal’s 23 amino
acids was cloned and purified as described earlier, ex-
cept that the 39 oligomer used for the PCR was 59ACATC-
CGATGACGGTACCTTAAGTCACTTTTATGTA39.
DHFR activity assay, determination of steady-state
kinetics, and inhibition constant
A modified version of the standard DHFR activity assay
was used to determine activity (Osborn and Huenne-
kens, 1958). The components of the assay were as fol-
lows: 50 mM dihydrofolic acid (prepared by dithionite
eduction of folic acid (Blakley, 1960)), 60 mM NADPH
(Sigma, St. Louis, MO) and 12 mM b-mercaptoethanol in
MATS buffer (25 mM 2-(N-morpholino)ethanesulfonate
[MES], 25 mM sodium acetate, 50 mM Tris, and 100 mM
NaCl). The decrease in absorbance at 340 nm was mea-
sured on a Beckman DU-70 spectrophotometer. Varying
concentrations of protein (60 ng–20 mg) were used to
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214 CINQUINA ET AL.test for activity. FH2 was added to initiate the reactions.
pecific activities of the protein samples were deter-
ined by measuring the slope of the initial linear portion
f the assay curve and then dividing by the extinction
oefficient for the reaction and the concentration of the
rotein sample. The millimolar extinction coefficient at
40 nm used for the reaction FH2 1 NADPH 3 FH4 1
ADP1 was 12.8 6 0.2 cm21 (Appleman et al., 1989). The
m values of KSHV-DHFR, rhDHFR, and ntKSHV-DHFR for
FH2 were determined over a range of FH2 concentrations
that did not exhibit substrate inhibition (0.1–8 mM for the
viral enzymes and 0.1–1 mM for rhDHFR) and 100 mM
ADPH. Km values for NADPH were determined by vary-
ing [NADPH] from 1 to 100 mM with a fixed concentration
f FH2 (8 mM for the viral enzymes, 1 mM for rhDHFR).
Plots of velocity (V) vs. [substrate] were created and fit to
a hyperbolic equation using Kaliedagraph software (Syn-
ergy Software), which generated the Km and Vmax values.
alues of kcat were determined from the equation Vmax 5
kcat[E]tot.
MTX, TMP, AMT, and PYR were obtained from Sigma.
PTX was generously donated by Dr. Debabrata Banerjee
in the laboratory of Dr. Joseph R. Bertino (at Memorial
Sloan-Kettering Cancer Center). For the K i analyses, the
concentration of each inhibitor was varied at fixed sub-
strate concentrations. Plots of V versus [I] were then fit to
the equation:
V 5
2A 1 ˛A 2 1 4K i,app[E]tot
2[E]tot
V0
as described by Appleman et al. (1988a). A 5 [I]tot 1 K i,app
2 [E]tot, [I]tot is the total concentration of inhibitor, [E]tot is
the total concentration of enzyme (3–14 nM), K i,app 5 K i(1
1 [FH2]/Km), and V0 is the reaction velocity without inhib-
itor. Fits were performed using the Kaliedagraph pro-
gram.
Tissue culture
The BJAB and Cl-16 cell lines were maintained in RPMI
plus 8% FCS; the BC-1, BC-3, BCBL-1, and HH-B2 cell
lines were maintained in RPMI plus 15% FCS; and 3 mM
n-butyrate (butyrate) was used to induce all cell lines into
lytic replication, except the BC-3 cell line (Miller et al.,
1997). For the BC-3 cell line, a combination of 3 mM
butyrate and 20 ng/mL TPA was used to induce the lytic
cycle.
Northern analysis
Whole-cell RNA extracts were prepared using the
RNeasy kit from Qiagen (Chatsworth, CA). The hDHFR
single-stranded oligonucleotide probe was complemen-
tary to an area of low nucleotide sequence identity in
the 59 region of the KSHV-DHFR gene. This oligonucleo-
tide was 59GTTCTGGGACACAGCGACGATGCAGTTTAGC-GAA39. The KSHV-DHFR oligonucleotide was comple-
mentary to the unique 39 region of the KSHV-DHFR gene
that encodes the unique 23-a.a. “tail” of the enzyme. This
oligonucleotide was 59CGAAGTCTCACTGAAGGGCGG-
GGTCGCGGGTCG39. The RNA extracts were separated
on a 1% agarose/10% formaldehyde gel. The RNA was
transferred to a NYTRAN filter, which was probed with
32P-radiolabeled DHFR olignucleotides. The amount of
otal cellular RNA contained in each sample was con-
rolled for by probing the blots for RNaseP.
estern analysis
Rabbit anti-KSHV-DHFR antibodies were raised by in-
ecting rabbits with viral DHFR that had been purified
rom E. coli. Rabbit anti-hDHFR antibodies were a gen-
rous contribution from Dr. Bruce Dolnick at SUNY Buf-
alo. Rabbit anti-hDHFR antibodies were also produced
y injecting rabbits with rhDHFR expressed in E. coli.
he rhDHFR expression vector was a generous contri-
ution from Dr. Debabrata Banerjee in the laboratory of
r. Joseph R. Bertino. The enzyme was purified as de-
cribed previously using methorexate sepharose (Sigma)
Prendergast et al., 1988).
Whole-cell extracts were sonicated, boiled, and
loaded onto 12% polyacrylamide gels. After electrophore-
sis, proteins were transferred onto a nitrocellulose mem-
brane, which was then incubated with antibody. 125I-
labeled protein A was used to detect the primary anti-
body. Mouse monoclonal anti-b-actin antibody (Sigma)
was used to control for loading.
Quantitation of KSHV-DHFR and hDHFR
Samples of purified KSHV-DHFR and rhDHFR were
quantitated by hydrolysis and subsequent ion exchange
chromatography at the protein analysis section of Yale’s
W. M. Keck Facility. These samples were used as stan-
dards for comparison with the amounts of DHFR present
in cell extracts for quantitative, 125I-protein A Western
blotting. A phosphorimager was used to compare the
amount of DHFR in the whole-cell samples to the amount
of purified DHFR in the standards.
Isolation of CD3-depleted human PBMCs
Blood obtained by venipuncture was collected in a
heparinized syringe. PBMCs were isolated over a Ficoll–
Hypaque gradient (ICN) by spinning at 300g for 30 min.
Cells were washed in PBS and resuspended at 2 3 107
cells/mL in PBS plus 2% fetal bovine serum. Antihuman
CD3-conjugated magnetic beads (Dynal, Fort Lee, NJ)
were added at manufacturer-recommended concentra-
tions and the cell/bead suspension was incubated at
4°C on a nutator for 45 min. Beads were depleted three
times using magnetic plates. Residual CD3-depleted
cells were washed in RPMI before cell extracts were
prepared for immunoblotting. The percentage of CD3-
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215DIHYDROFOLATE REDUCTASE FROM KSHVpositive cells was determined by cell-surface staining
using anti-CD-3 FITC-conjugated antibodies (Sigma) and
subsequent FACS analysis. After depletion, the percent-
age of CD3-positive cells was less than 3%.
Intracellular localization of rhDHFR, KSHV-DHFR, -TS,
-TK, -RRa, -RRb
rhDHFR, KSHV-DHFR, –TS, -TK, -RRa, -RRb were
cloned into the pCMV-tag2 vector (Stratagene, La Jolla,
CA). The primers used to clone these genes from the
BC-3 cell line DNA were as follows: rhDHFR 59: 59GAA-
TTCGATATCCAAGCTTATGGTTGGTTCGCTA39, rhDHFR
39: 59ACATCCGATGACCTCGAGTTAATCATTCTTCTC39,
KSHV-DHFR 59: 59TCCGGACTCAGATCTCGAGCTATG-
ATCCTACACTT39, KSHV-DHFR 39: 59ACATCCGAT-
ACGGTACCTTACGAAGTCTCACT39, 24a.a. C-terminal
SHV-DHFR truncation mutant 39: 59ACATCCGA-
GACCTCGAGTTAAGTCACTTTTATGTA39, KSHV-TS
9: 59GCATTATCGGATCCATGTTTCCGTTTGTACCT39,
KSHV-TS 39: 59GATATCCTCGAGCTATACTGCCATTTC-
CATACG39, KSHV-TK 59: 59GATATCAAGCTTATGGCA-
AAGGCGGTTTT39, KSHV-TK 39: GATATCCTCGAGCTA-
ACCCTGCATGTCTC39, KSHV-RRa 59: 59GATATCG-
GATCCATGTCTGTCCGGACATTT39, KSHV-RRa 39:
59GATATCCTCGAGCTACTGACAGACCAGGCACTC39,
SHV-RRb 59: 59GATATCGGATCCATGGATTCAGTT-
GATCGA39, KSHV-RRb 39: 59GATATCCTCGAGTCA-
AAATCGTCAGTCAC39. These genes were cloned in-
rame with an N-terminal flag tag. CHO cells were trans-
ected with either vector alone or a flag-tagged gene
sing Lipofectamine (Gibco-BRL). Transfected cells were
ixed on coverslips with 2% paraformaldehyde and incu-
ated with mouse monoclonal antiflag M2 antibody
Stratagene). Cells were then incubated with goat anti-
ouse IgG TRITC conjugated antibody (Sigma). Images
ere obtained using a Bio-Rad confocal microscope at
agnification 6303.
ffects of AMT on KSHV replication in culture
To control for the toxic effects of AMT, BC-3 cells were
lowly adapted to growth in HAT media (Gibco-BRL)
onsisting of 100 mM hypoxanthine (H), 16 mM thymidine
T), and 400 nM AMT. When the adapted cells were in
ogarithmic growth, they were washed three times in
upplement-free media. Cells were then subcultured in
edia containing either no supplement, HT alone, HAT,
r AMT (400 nM). Cells which were uninduced or treated
ith TPA and butyrate (as described earlier) were har-
ested after 48 and 72 h. For Southern analysis, the
Neasy kit (Qiagen) was used to extract genomic DNA.
hese samples were digested with EcoRI and separated
n a 1% agarose gel. The samples were transferred to a
itrocellulose membrane and probed with a 32P-labeled
35-bp BamHI to XhoI fragment encompassing KSHV
RF65 from bp 112443 to 111931. Loading was controlled
Bor by probing the blot with a 32P-labeled 1.8-kb portion of
b-actin cDNA. Whole-cell extracts prepared in SDS sam-
ple buffer were separated on 12% acrylamide gels. The
resulting immunoblot was then probed with rabbit
a-KSHV small capsid antigen (sVCA) antibodies (Lin et
al., 1997). Mouse monoclonal anti-b-actin antibodies
ere used to control for protein loading. 125I-labeled
protein A was used to detect the primary antibody.
The resulting bands were quantified using a phosphor-
imager.
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